INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 146 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $7,649,000 | +234.2% | 548,459 | +290.1% | 0.11% | +278.6% |
| Q1 2022 | $2,289,000 | +522.0% | 140,600 | +522.1% | 0.03% | +600.0% |
| Q4 2021 | $368,000 | -59.7% | 22,600 | -38.9% | 0.00% | -81.0% |
| Q4 2020 | $913,000 | -48.8% | 36,971 | -14.0% | 0.02% | -48.8% |
| Q3 2020 | $1,783,000 | +43.0% | 43,000 | +65.4% | 0.04% | -2.4% |
| Q2 2020 | $1,247,000 | -54.1% | 26,000 | -39.8% | 0.04% | -72.7% |
| Q1 2020 | $2,719,000 | -50.7% | 43,200 | -2.9% | 0.15% | -17.2% |
| Q4 2019 | $5,515,000 | +219.7% | 44,500 | +71.2% | 0.19% | +109.0% |
| Q3 2019 | $1,725,000 | -89.0% | 26,000 | -81.5% | 0.09% | -89.7% |
| Q1 2019 | $15,694,000 | – | 140,300 | – | 0.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |